Skip to main content

Table 1 Summary of interventions, study details, results and quality of evidence

From: Interventions for post-infectious irritable bowel syndrome: a systematic review of treatment efficacy

Source

N (Intervention: Placebo)

Study Type

PI-IBS inclusion criteria

Intervention (Type, dose, length of intervention, frequency)

Duration of intervention

Outcome(s)

Quality of evidence (modified GRADE [17])

Bafutto et al., 2011

61 (18:43)

cohort

Rome III with IBS-D, as reported by patient

- Mesalazine

30 days

- stool frequency decreased by 1.33 stools/day on average

Moderate

- 30 days

The study is unclear as to how the randomization and allocation concealment were conducted.

- 800 mg

- TID

- stool form and consistency improved by 2.17 based on the Bristol stool scale (16)

Hanevik et al., 2011

18 (11:7)

RCT

History of giardiasis 2 years prior and Rome II criteria

- Mesalazine

6 weeks

- no significant change in symptoms following mesalazine treatment

Low

- 6 weeks

The study was a pilot study with small sample. It is unclear as to how to randomization and allocation concealment were conducted

- 800 mg

- BID

Tuteja et al., 2012

20 (10:10)

RCT

Onset of IBS symptoms in previously asymptomatic individuals after acute gastroenteritis characterized by two or more of: diarrhea, vomiting, fever, as reported by the patient

- Mesalamine

12 weeks

- no significant change in symptoms following mesalazine treatment

Low

- 12 weeks

Insufficient sample size

- 1.6 g

- BID

Dizdar et al., 2007

34 (15:39)

RCT

Persisting abdominal symptoms 12 months after Giardia infection and Rome II criteria, as reported by Giardia outpatient clinic

- Ondansetron

2 days

- no significant improvement in symptoms after ondansetron treatment - Significant improvement in post-prandial nausea score before vs after ondanestron treatment (27.47 ± 21.89 vs 41.40 ± 23.04)

Moderate

- 2 days

Small sample size

- 8 mg

- QD

Dunlop et al., 2003

34 (20:14)

RCT

New bowel symptoms in a previously asymptomatic individuals immediately after an acute illness characterized by two or more of: diarrhea, fever, vomiting, positive stool culture, as recorded by the patient or gastroenterology clinic

- Prednisone

21 days

- No improvement in abdominal pain, diarrhea, frequency or urgency based on a gastrointestinal symptom rating scale

Moderate

- 21 days

Small sample size

- 30 mg

- QD

Menon et al., 2011

25 (15:10)

Retrospective

History of an acute gastroenteritis precipitating chronic diarrhea, as reported in clinic notes and hospital database

- Cholestyramine

Variable (1–15 years)

- decrease in diarrhea frequency of 5.9 stools/day

Low

- 1–15 years

Retrospective study that only included people with bile acid malabsorption and infectious gastroenteritis.

- 8.22 g

- QD

Niaz et al., 1997

16 (16:0)

Retrospective

History of an acute gastroenteritis precipitating chronic diarrhea defined as distinct change in bowel habit with 4–15 loose watery motions per day as reported by the patient

- Cholestyramine

2 weeks

- decreased stool frequency of 5.1 stools/day

Low

- 2 weeks

Retrospective study that only included people with bile acid malabsorption and infectious gastroenteritis.

- 2–16 g

- QD

Thakur et al., 2009

76 (17:59)

RCT

Rome II criteria and history of gastroenteritis or dysentery as reported by the patient

-Metronidazole

7 days

- improvement in pain, stool and total symptom scores at days 7 and 28

Low

Study was not randomized, and both patient and physician were not blinded. 9 patients were lost to follow-up but it is unclear if they were included in analysis.

- 4 weeks

- 400 mg

- TID

- stool symptoms continued to improve between day 7 and 28 even though patients were no longer taking the medication

Lifshitz et al., 1990

29 (10:19)

RCT

History of chronic diarrhea after an episode of gastroenteritis lasting more than 3 weeks as reported by Pediatric Gastroenterology unit

- Pregestimil

variable

- 9 out of 10 infants had improved clinical symptoms, shorter time to improvement

Moderate

- 3 – 7 days

Population was limited to infants with lactose intolerance. Inclusion was based on chronic diarrhea, not on established criteria such as Rome criteria.

- 1500 mL/kg

- Daily to provide 70 kcal/kg